Corrigendum to ‘‘Design, structure–activity relationship, and highly
efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine
derivatives as novel neurokinin-1 receptor antagonists’’
[Bioorg. Med. Chem. 19 (2011) 6430–6446]
Junya Shiraia,⇑, Takeshi Yoshikawaa, Masayuki Yamashitab, Yasuharu Yamamotoa, Makiko Kawamotoa,
Naoki Taruia, Izumi Kamoa, Tadatoshi Hashimotoa, Yoshinori Ikeuraa
aPharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan
bCMC Center, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan
The starting compound 2 had been designed and synthesized
for the biological activity by Mr. Yamaoka and Dr. Yukimasa
although the compound was found as a HTS hit. However, the
achievement of them was not reflected in the original paper.
Therefore, we would like to revise the description of the origin of
the starting compound 2 and acknowledge them.
0968-0896/? 2014 Elsevier Ltd. All rights reserved.
DOI of original article: http://dx.doi.org/10.1016/j.bmc.2011.08.070
⇑Corresponding author. Tel.: +81 6 6300 6673; fax: +81 6 6300 6306.
E-mail address: Shirai_Junya@takeda.co.jp (J. Shirai).
Bioorganic & Medicinal Chemistry 22 (2014) 2379
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier.com/locate/bmc